Form 4: Avidity Biosciences Chief Program Officer Sells Shares Following RSU Vesting
SEC Form 4 Filing
Avidity Biosciences' Chief Program Officer, Kathleen P. Gallagher, sold a total of 9,411 shares of common stock in multiple transactions on January 21 and 22, 2025, primarily to cover tax obligations related to vesting of Restricted Stock Units (RSUs).
Summary
- Kathleen P. Gallagher, Chief Program Officer at Avidity Biosciences, sold shares of the company's common stock on January 21 and 22, 2025.
- The sales on January 21, 2025, involved 1,295 shares at $28.59, 670 shares at a weighted average price of $28.5953, and 1,817 shares at a weighted average price of $28.593.
- On January 22, 2025, 5,629 shares were sold at a weighted average price of $30.1609.
- The sales on January 21, 2025, included shares sold to cover tax withholding obligations related to the vesting of RSUs on January 20, 2025.
- These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2024.
- Following these transactions, Ms. Gallagher beneficially owns 50,554 shares of Avidity Biosciences common stock.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction related to insider stock sales for tax purposes. It is neither particularly positive nor negative.
Industry Context
This is a routine filing related to insider trading activity, specifically the sale of shares by a company officer. Such filings are common and expected, especially after the vesting of equity compensation.
Comparison to Industry Standards
- The use of a Rule 10b5-1 trading plan is a common practice among corporate executives to avoid accusations of insider trading.
- The 'sell-to-cover' mechanism for tax obligations is a standard feature of many equity compensation plans.
- The price ranges of the sales are within the expected volatility of the stock.
Stakeholder Impact
- The stock sales may have a minor impact on the stock price, but the transactions are not expected to significantly affect the company's operations or long-term prospects.
Key Dates
| Date | Description |
|---|---|
| 2024-06-12 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 2025-01-20 | Date of RSU vesting that triggered tax withholding obligations. |
| 2025-01-21 | Date of the first set of stock sales by the Reporting Person. |
| 2025-01-22 | Date of the second set of stock sales by the Reporting Person. |
| 2025-01-23 | Date the Form 4 was signed. |
Keywords
Avidity Biosciences, Kathleen P. Gallagher, insider trading, stock sale, Rule 10b5-1, RSU, tax withholding, equity compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.